Effective treatment of bacterial prostatitis is limited by poor antibiotic penetration into prostatic tissue due to anatomical and physiological barriers, including the blood-prostate barrier, pH-dependent ion trapping, and protein binding. A systematic review was conducted to evaluate the intraprostatic pharmacokinetics of antibiotics. PubMed, Embase, and Medline were searched up to December 2024. In total, 44 studies reporting antibiotic concentrations in serum, prostate tissue, or prostatic fluids were included. Prostate tissue-to-serum ratios (PT/S) and pharmacokinetic parameters were analyzed to assess prostate penetration. A total of 44 studies were included. Fluoroquinolones consistently demonstrated favorable intraprostatic penetration (PT/S ≥ 1), supporting their role as first-line agents. Trimethoprim-sulfamethoxazole (TMP-SMX) showed moderate penetration driven primarily by trimethoprim, while macrolides and tetracyclines exhibited variable but measurable distribution. Most β-lactams penetrated poorly into non-inflamed prostate tissue, although selected cephalosporins achieved moderate concentrations in acute inflammatory settings. Fosfomycin showed variable intraprostatic exposure, indicating that tissue diffusion does not uniformly translate into clinical efficacy, particularly in chronic disease. Antibiotic efficacy in prostatitis is strongly influenced by intraprostatic pharmacokinetics rather than drug class alone. Integrating physicochemical properties, disease subtype, and clinical guideline recommendations is essential for rational antibiotic selection and optimized treatment strategies.
The intrapatient variability (IPV) of tacrolimus (Tac) has gradually become a new index for the prognosis of organ transplantation. The gene polymorphism is involved in the pharmacokinetic process of Tac. The aim of this study was to investigate the effects of genetic polymorphisms on Tac IPV and other clinical outcomes in heart transplant recipients during the early post-transplantation period. Our study retrospectively collected the clinical data and genotyping results of 48 heart transplant recipients. SPSS (21.0) and Graphpad Prism (8.0) were used to analyze the effect of gene polymorphism on Tac concentration (C0) and clinical outcome. The CYP3A5 rs15524 AA genotype has a higher trough concentrations/dose (C0/D) value than G allele carriers, and CYP3A7 rs776744 CC genotype has a higher C0/D value than T allele carriers. Patients with The CYP3A5 rs15524 and CYP3A7 rs776744 mutants had a higher IPV. One year after heart transplantation, the mortality of wild-type and mutant CYP3A5 rs15524 patients due to rejection was 0 vs. 10.7% (P = 0.255). The mortality caused by rejection in wild-type patients and mutant patients of CYP3A7 rs776744 was 4.5% vs. 7.7% (p = 0.564). Genetic polymorphisms of CYP3A5 rs15524 and CYP3A7 rs776744 affect tacrolimus metabolism in heart transplant recipients, significantly affecting Tac C0/D during the early postoperative period. In addition, gene polymorphism may be related to Tac IPV and clinical outcome in patients with early heart transplantation.
This study aimed to investigate the effects of genetic polymorphisms on tacrolimus blood levels and intra-individual variability in recipients of heart transplants during the early post-transplantation period. Demographic information, concomitant medications, daily tacrolimus dose, trough concentration, and physiological and biochemical information of 87 Chinese recipients of heart transplants were collected. Trough concentrations were determined using a chemiluminescent micro-particle immunoassay, and 17 selected single nucleic acid polymorphisms were genotyped by direct sequencing. We assessed intra-individual variability by calculating the coefficient of variation of tacrolimus trough concentration and analyzed factors associated with tacrolimus concentration and intra-individual variability. Our study found that low body weight and a high percentage of neutrophils significantly influenced the coefficient of variation of tacrolimus. CYP3A5*1D and CYP3A7 rs776744 haplotypes correlated significantly with an intra-individual coefficient of variation of tacrolimus trough concentration during the early postoperative period. Patients with the CYP3A5*1D rs15524 and CYP3A7 rs776744 TT haplotype had a higher coefficient of variation than carriers of the C allele. Genetic polymorphisms in recipients of heart transplants affect tacrolimus metabolism, significantly affecting tacrolimus blood concentration during the early postoperative period. Genotyping before drug administration can help optimize dosing regimens, reduce intra-individual variability, and improve prognosis.